Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal
|
August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
JACC. Cardiooncology
|
January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
Roberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure
|
April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial
Roberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal
|
August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
JACC. Cardiooncology
|
January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
Roberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure
|
April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial
Roberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
Page
of 12